Dasatinib dosage in the treatment of acute myeloid leukemia

The dosage of dasatinib in the treatment of acute myeloid leukemia is a key issue because it is directly related to the therapeutic effect and safety of patients.

Dasatinib, trade nameSPRYCEL, is a treatment drug for a variety of leukemias, developed by AstraZeneca of the United States. It is approved to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). In the treatment of acute myeloid leukemia, dasatinib has also shown certain efficacy.

For patients with Ph+chronic phase CML, the recommended starting dose is 100mg taken orally once daily. This dosage is based on the patient's tolerance and response to the drug. For patients with Ph+accelerated phase, blast phaseCML or Ph+ALL, the recommended starting dose is 70 mg, taken orally twice a day in the morning and evening. This adjustment is to better control the condition and reduce the occurrence of adverse reactions.

During treatment, doctors will adjust the dose based on the patient's response and tolerance. If a patient does not respond well to the initial dose or develops tolerability issues, the doctor may consider increasing or decreasing the dose. For some special cases, such as elderly patients or patients with liver damage, doctors will pay special attention to dosage selection and adjustment to ensure the safety and effectiveness of the treatment.

Dasatinib should be taken at the same time each time to ensure a stable concentration of the drug in the body. Dasatinib tablets must not be crushed or cut and must be swallowed whole to ensure integrity and stable release of the drug. Dasatinib can be taken with food or on an empty stomach. Food has little effect on its absorption. During the treatment process, doctors will regularly monitor the patient's response and disease progression, and adjust the treatment plan in a timely manner.